Gunter Von Minckwitz
Experienced in Anemia

Gunter Von Minckwitz

Martin Behaim Str. 12, 
Neu Isenburg, HE, DE 
Experienced in Anemia
Martin Behaim Str. 12, 
Neu Isenburg, HE, DE 
OverviewLocationsClinical Research

Overview

Gunter Von Minckwitz practices in Neu Isenburg, Germany. Mr. Von Minckwitz is rated as an Experienced expert by MediFind in the treatment of Anemia. His top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Febrile Neutropenia, and Mastectomy.

His clinical research consists of co-authoring 304 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Anemia.

Gender
Male

Locations

Martin Behaim Str. 12, Neu Isenburg, HE 63263, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients With Hormone-receptor-positive, HER2-normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy PENELOPEB
Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients With Hormone-receptor-positive, HER2-normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy PENELOPEB
Enrollment Status: Completed
Publish Date: December 12, 2023
Intervention Type: Drug
Study Drug: Palbociclib PD-0332991
Study Phase: Phase 3

303 Total Publications

Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288].
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Oncology (2019), volume 30:1279-1288].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 20, 2022

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Von Minckwitz's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile